Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Spiderwort Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions in the portfolio. These actions are being handled by 2 distinct examiners in 2 distinct art units. BABSON, NICOLE PLOURDE is the busiest examiner, with 1 pending office action. The 2 pending office actions are uniquely assigned, with each action being reviewed by a different examiner in a different art unit.
This distribution between 2 distinct art units suggests that the company's Biotechnology & Pharmaceuticals innovations are being evaluated in two distinct technical contexts. BABSON, NICOLE PLOURDE is responsible for 1 pending office action, which represents a portion of the current pending workload. Practitioners must prepare for two separate prosecution tracks, as the 2 pending office actions are subject to different examiner preferences and art unit standards. This structure requires a tailored approach for each of the 2 pending office actions to ensure consistent progress across the portfolio. The presence of 2 distinct examiners ensures individual attention for each matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BABSON, NICOLE PLOURDE | 1 | 46.7% | +33.7% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611042 | HIGH-DENSITY MICROCHANNELS | ROGERS, ERIC JASON | 19d overdue |
| 18034455 | PLANT-DERIVED AEROGELS, HYDROGELS, AND FOAMS, AND METHODS AND USES THEREOF | BABSON, NICOLE PLOURDE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611042 | HIGH-DENSITY MICROCHANNELS | ROGERS, ERIC JASON | 19d overdue |
| 18034455 | PLANT-DERIVED AEROGELS, HYDROGELS, AND FOAMS, AND METHODS AND USES THEREOF | BABSON, NICOLE PLOURDE | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034455 | PLANT-DERIVED AEROGELS, HYDROGELS, AND FOAMS, AND METHODS AND USES THEREOF | BABSON, NICOLE PLOURDE | 1619 | §102§103§112Other | Final Rejection | — | Pending | Apr 28, 2023 |
| 17611042 | HIGH-DENSITY MICROCHANNELS | ROGERS, ERIC JASON | 1638 | §101§102§103§112DP | Final Rejection | 19d overdue | Pending | Nov 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpiderwort Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Nicole Plourde Babson has the most, with 1 of Spiderwort Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
